Spruce Street Capital LP
13F Reported Value
ⓘ$415.9M
Holdings
28
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Spruce Street Capital LP disclosed 28 positions worth $415.9M in its Form 13F-HR for Q1 2026, led by $RLMD (RELMADA THERAPEUTICS, INC.) at 10.3% of the equity portfolio, followed by $KNSA and $LBRX. During the quarter the fund opened 7 new positions and exited 6 — including a new stake in $ALKS. The portfolio is most concentrated in Healthcare (98.8% of disclosed assets). All figures are sourced directly from Spruce Street Capital LP’s Form 13F-HR filing with the SEC under CIK 2050194.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$43.0M6,262,114 sh - $36.6M761,063 sh
- —
Quality
$33.6M1,376,159 sh - 26.8
Quality
$31.3M373,274 sh - 12.7
Quality
$29.7M2,984,125 sh - —
Quality
$29.1M1,325,210 sh - —
Quality
$19.5M489,849 sh - —
Quality
$18.5M3,383,175 sh - 25.9
Quality
$18.1M897,681 sh - —
Quality
$14.3M245,709 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 RELMADA THERAPEUTICS, INC.$RLMD | — | $43.0M | 6,262,114 |
 Kiniksa Pharmaceuticals International, plc$KNSA | — | $36.6M | 761,063 |
 LB PHARMACEUTICALS INC$LBRX | — | $33.6M | 1,376,159 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8 | $31.3M | 373,274 |
 Relay Therapeutics, Inc.$RLAY | 12.7 | $29.7M | 2,984,125 |
 Alto Neuroscience, Inc.$ANRO | — | $29.1M | 1,325,210 |
 Centessa Pharmaceuticals plc$CNTA | — | $19.5M | 489,849 |
 Savara Inc$SVRA | — | $18.5M | 3,383,175 |
 KalVista Pharmaceuticals, Inc.$KALV | 25.9 | $18.1M | 897,681 |
 Vaxcyte, Inc.$PCVX | — | $14.3M | 245,709 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Spruce Street Capital LP's 28 positions.
Showing top 10 of 28 holdings.
Sector Allocation
Healthcare
$410.9M
Other
$5.1M
Full Holdings — Spruce Street Capital LP (Q1 2026)
All 28 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RLMD | RELMADA THERAPEUTICS, INC. | $43.0M | 10.3% | +53% | — |
| 2 | $KNSA | Kiniksa Pharmaceuticals International, plc | $36.6M | 8.8% | +75% | — |
| 3 | $LBRX | LB PHARMACEUTICALS INC | $33.6M | 8.1% | +37% | — |
| 4 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $31.3M | 7.5% | +25% | 26.8 |
| 5 | $RLAY | Relay Therapeutics, Inc. | $29.7M | 7.1% | +0% | 12.7 |
| 6 | $ANRO | Alto Neuroscience, Inc. | $29.1M | 7.0% | +495% | — |
| 7 | $CNTA | Centessa Pharmaceuticals plc | $19.5M | 4.7% | +528% | — |
| 8 | $SVRA | Savara Inc | $18.5M | 4.4% | +40% | — |
| 9 | $KALV | KalVista Pharmaceuticals, Inc. | $18.1M | 4.3% | +131% | 25.9 |
| 10 | $PCVX | Vaxcyte, Inc. | $14.3M | 3.4% | -39% | — |
| 11 |  $ELVN | Enliven Therapeutics, Inc. | $12.9M | 3.1% | -26% | — |
| 12 |  $SRZN | Surrozen, Inc./DE | $12.6M | 3.0% | +0% | — |
| 13 |  $ENTA | ENANTA PHARMACEUTICALS INC | $11.8M | 2.8% | +139% | 15.5 |
| 14 |  $ALKS | Alkermes plc. | $11.2M | 2.7% | NEW | — |
| 15 |  $CATX | Perspective Therapeutics, Inc. | $11.0M | 2.6% | NEW | — |
| 16 |  $NERV | Minerva Neurosciences, Inc. | $10.0M | 2.4% | +0% | — |
| 17 |  $IPSC | Century Therapeutics, Inc. | $9.2M | 2.2% | +186% | 43.5 |
| 18 |  $ALMS | ALUMIS INC. | $8.6M | 2.1% | NEW | 9.2 |
| 19 |  $SABS | SAB Biotherapeutics, Inc. | $8.4M | 2.0% | +0% | — |
| 20 |  $ERAS | Erasca, Inc. | $6.8M | 1.6% | -89% | — |
| 21 |  $IKT | Inhibikase Therapeutics, Inc. | $6.0M | 1.4% | +0% | — |
| 22 |  $MAZE | Maze Therapeutics, Inc. | $6.0M | 1.4% | NEW | 19.7 |
| 23 |  $ANTX | AN2 Therapeutics, Inc. | $5.6M | 1.3% | NEW | — |
| 24 |  $LXEO | Lexeo Therapeutics, Inc. | $5.3M | 1.3% | +431% | — |
| 25 | — | HELIX ACQUISITION CORP III | $5.1M | 1.2% | NEW | — |
| 26 |  $ALEC | Alector, Inc. | $4.5M | 1.1% | +88% | 8.9 |
| 27 |  $LONA | LeonaBio, Inc. | $3.8M | 0.9% | +0% | — |
| 28 |  $CRVS | Corvus Pharmaceuticals, Inc. | $3.4M | 0.8% | NEW | — |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Spruce Street Capital LP including:
Track Spruce Street Capital LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Spruce Street Capital LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Spruce Street Capital LP
13F Pro is an AI hedge fund tracker and stock research platform. For Spruce Street Capital LP (SEC CIK: 2050194), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Spruce Street Capital LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.